JP2022095908A5 - - Google Patents

Download PDF

Info

Publication number
JP2022095908A5
JP2022095908A5 JP2022067540A JP2022067540A JP2022095908A5 JP 2022095908 A5 JP2022095908 A5 JP 2022095908A5 JP 2022067540 A JP2022067540 A JP 2022067540A JP 2022067540 A JP2022067540 A JP 2022067540A JP 2022095908 A5 JP2022095908 A5 JP 2022095908A5
Authority
JP
Japan
Prior art keywords
therapeutic agent
cancer
her2
antibody
agent according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022067540A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022095908A (ja
Filing date
Publication date
Priority claimed from JP2018543951A external-priority patent/JPWO2018066626A1/ja
Application filed filed Critical
Publication of JP2022095908A publication Critical patent/JP2022095908A/ja
Publication of JP2022095908A5 publication Critical patent/JP2022095908A5/ja
Priority to JP2024016749A priority Critical patent/JP2024054226A/ja
Priority to JP2025201784A priority patent/JP2026035673A/ja
Pending legal-status Critical Current

Links

JP2022067540A 2016-10-07 2022-04-15 抗her2抗体-薬物コンジュゲート投与による耐性癌の治療 Pending JP2022095908A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024016749A JP2024054226A (ja) 2016-10-07 2024-02-07 抗her2抗体-薬物コンジュゲート投与による耐性癌の治療
JP2025201784A JP2026035673A (ja) 2016-10-07 2025-11-21 抗her2抗体-薬物コンジュゲート投与による耐性癌の治療

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
JP2016199341 2016-10-07
JP2016199341 2016-10-07
JP2017097589 2017-05-16
JP2017097589 2017-05-16
JP2017172814 2017-09-08
JP2017172814 2017-09-08
JP2018543951A JPWO2018066626A1 (ja) 2016-10-07 2017-10-05 抗her2抗体−薬物コンジュゲート投与による耐性癌の治療
PCT/JP2017/036215 WO2018066626A1 (ja) 2016-10-07 2017-10-05 抗her2抗体-薬物コンジュゲート投与による耐性癌の治療

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018543951A Division JPWO2018066626A1 (ja) 2016-10-07 2017-10-05 抗her2抗体−薬物コンジュゲート投与による耐性癌の治療

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024016749A Division JP2024054226A (ja) 2016-10-07 2024-02-07 抗her2抗体-薬物コンジュゲート投与による耐性癌の治療

Publications (2)

Publication Number Publication Date
JP2022095908A JP2022095908A (ja) 2022-06-28
JP2022095908A5 true JP2022095908A5 (enExample) 2023-03-08

Family

ID=61831486

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018543951A Pending JPWO2018066626A1 (ja) 2016-10-07 2017-10-05 抗her2抗体−薬物コンジュゲート投与による耐性癌の治療
JP2022067540A Pending JP2022095908A (ja) 2016-10-07 2022-04-15 抗her2抗体-薬物コンジュゲート投与による耐性癌の治療
JP2024016749A Withdrawn JP2024054226A (ja) 2016-10-07 2024-02-07 抗her2抗体-薬物コンジュゲート投与による耐性癌の治療
JP2025201784A Pending JP2026035673A (ja) 2016-10-07 2025-11-21 抗her2抗体-薬物コンジュゲート投与による耐性癌の治療

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018543951A Pending JPWO2018066626A1 (ja) 2016-10-07 2017-10-05 抗her2抗体−薬物コンジュゲート投与による耐性癌の治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024016749A Withdrawn JP2024054226A (ja) 2016-10-07 2024-02-07 抗her2抗体-薬物コンジュゲート投与による耐性癌の治療
JP2025201784A Pending JP2026035673A (ja) 2016-10-07 2025-11-21 抗her2抗体-薬物コンジュゲート投与による耐性癌の治療

Country Status (11)

Country Link
US (1) US12698342B2 (enExample)
EP (1) EP3524267A4 (enExample)
JP (4) JPWO2018066626A1 (enExample)
KR (2) KR20190066026A (enExample)
CN (1) CN109789211A (enExample)
AU (2) AU2017341000B2 (enExample)
BR (1) BR112019005247A2 (enExample)
CA (1) CA3036941C (enExample)
SG (1) SG10201912173RA (enExample)
TW (2) TWI868465B (enExample)
WO (1) WO2018066626A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250004902A (ko) * 2017-08-23 2025-01-08 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트의 제제 및 그 동결 건조 방법
US20190194348A1 (en) * 2017-11-10 2019-06-27 Oregon Health & Science University Treatment of therapy-resistant her-2 positive breast cancer
CN112153989B (zh) * 2018-05-28 2025-07-29 第一三共株式会社 通过施用抗her2抗体-药物缀合物治疗her2突变的癌
SG11202100653YA (en) * 2018-07-25 2021-02-25 Daiichi Sankyo Co Ltd Effective method for manufacturing antibody-drug conjugate
EP3831853A4 (en) 2018-07-27 2022-06-01 Daiichi Sankyo Company, Limited ANTIBODY-DRUG CONJUGATE PROTEIN-RECOGNIZING DRUG UNIT
IL325918A (en) 2018-07-31 2026-03-01 Daiichi Sankyo Co Ltd Antibody-drug conjugates for use in the treatment of metastatic brain tumor
CN111655295B (zh) 2018-08-29 2024-05-28 荣昌生物制药(烟台)股份有限公司 抗her2抗体药物偶联物在治疗尿路上皮癌中的用途
CN118846110A (zh) 2018-09-06 2024-10-29 第一三共株式会社 抗体药物偶联物
KR20240104214A (ko) 2019-03-29 2024-07-04 메디뮨 리미티드 화합물 및 이의 접합체
CA3159770A1 (en) 2019-11-15 2021-05-20 Seagen Inc. Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
US12029736B2 (en) 2020-02-25 2024-07-09 Mediboston Limited Camptothecin derivatives and conjugates thereof
IL300030A (en) 2020-07-20 2023-03-01 Daiichi Sankyo Co Ltd Combination of an anti-2HER drug-antibody conjugate with a dimerization suppressor
DK4516357T3 (da) * 2020-09-30 2026-04-27 Duality Biologics Suzhou Co Ltd Antitumorforbindelse, fremgangsmåde til fremstilling deraf og anvendelse deraf
KR102247908B1 (ko) * 2020-10-08 2021-05-06 주식회사 엠디엡투스 Her2 압타머-항암 약물 복합체 및 이의 용도
WO2022099762A1 (zh) * 2020-11-12 2022-05-19 博瑞生物医药(苏州)股份有限公司 一种抗体偶联物中间体及其制备方法
AU2021394411A1 (en) * 2020-12-11 2023-07-06 Wigen Biomedicine Technology (shanghai) Co., Ltd. Novel camptothecin derivative, composition containing same, and use thereof
US12521444B2 (en) * 2021-02-25 2026-01-13 Fortvita Biologics Limited Anti-HER2 antibody-drug conjugates and uses thereof
CN117750980A (zh) * 2021-05-24 2024-03-22 荣昌生物制药(烟台)股份有限公司 Her2靶向抗体-药物偶联物用于治疗her2低表达乳腺癌的用途
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
CA3224492A1 (en) 2021-07-19 2023-01-26 Xiaojun Han Immunoconjugates and methods
CN118955614B (zh) * 2022-07-05 2025-12-30 上海药明合联生物技术有限公司 偶联连接子

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
JP3008226B2 (ja) 1991-01-16 2000-02-14 第一製薬株式会社 六環性化合物
US5658920A (en) 1991-01-16 1997-08-19 Daiichi Pharmaceutical Co., Ltd. Substituted 1H,12H-benz-[DE]pyrano[3',4':6,7] indolizino[1,2-B]quinoline-10,13(9H,15H)-dione compound
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
EP0656941B1 (en) 1992-03-24 2005-06-01 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
CA2177367A1 (en) 1993-12-03 1995-06-08 Andrew David Griffiths Recombinant binding proteins and peptides
JPH08337584A (ja) 1995-04-10 1996-12-24 Dai Ichi Seiyaku Co Ltd 縮合六環式アミノ化合物、これを含有する医薬及びその製法
US6504029B1 (en) 1995-04-10 2003-01-07 Daiichi Pharmaceutical Co., Ltd. Condensed-hexacyclic compounds and a process therefor
SG50747A1 (en) 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
JPH1095802A (ja) 1995-12-28 1998-04-14 Tanabe Seiyaku Co Ltd カンプトテシン誘導体
CA2192725C (en) 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
TW409058B (en) 1996-06-06 2000-10-21 Daiichi Seiyaku Co Method for preparation of a drug complex
JPH1171280A (ja) 1997-06-26 1999-03-16 Tanabe Seiyaku Co Ltd 医薬組成物
JPH1192405A (ja) 1997-09-19 1999-04-06 Dai Ichi Seiyaku Co Ltd 薬物複合体
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
WO1999061061A1 (fr) 1998-05-22 1999-12-02 Daiichi Pharmaceutical Co., Ltd. Composites medicamenteux
MXPA01004239A (es) 1998-10-30 2002-06-04 Daiichi Seiyaku Co Compuesto dds y metodo para la medicion del mismo.
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
EP2977063A1 (en) 1999-06-25 2016-01-27 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
AR024464A1 (es) 1999-06-25 2002-10-02 Genentech Inc Anticuerpos anti-erbb2 humanizados.
JP2002060351A (ja) 2000-03-22 2002-02-26 Dai Ichi Seiyaku Co Ltd 水酸基を有する薬物を含むdds化合物
BR0112287A (pt) 2000-06-29 2003-05-06 Daiichi Seiyaku Co Composto dds e seu método de preparação
AU2001271037A1 (en) 2000-07-13 2002-01-30 Daiichi Pharmaceutical Co., Ltd. Pharmaceutical compositions containing dds compounds
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
US20050123536A1 (en) 2001-11-20 2005-06-09 Che-Leung Law Treatment of immunological disorders using anti-dc30 antibodies
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US9745380B2 (en) 2002-03-01 2017-08-29 Immunomedics, Inc. RS7 antibodies
CA2508831C (en) 2002-12-13 2012-05-01 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
US7837980B2 (en) 2004-03-02 2010-11-23 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
BRPI0510909A2 (pt) 2004-05-19 2008-12-16 Medarex Inc composto de ligaÇço fÁrmaco-ligante citotàxico, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula e mÉtodo para retardar ou interromper o crescimento de tumor
NZ551180A (en) 2004-06-01 2009-10-30 Genentech Inc Antibody drug conjugates and methods
UA90480C2 (uk) 2004-07-22 2010-05-11 Джэнэнтэк, Инк. Фармацевтична композиція, що має протипухлинну активність, яка включає антитіло до her2
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US20080305044A1 (en) 2004-11-29 2008-12-11 Seattle Genetics, Inc. Engineered Antibodies and Immunoconjugates
DE102005009084A1 (de) 2005-02-28 2006-08-31 Ktb Tumorforschungsgesellschaft Mbh Proteinbindende Anthrazyklin-Peptid-Derivate und diese enthaltende Arzneimittel
DE102005009099A1 (de) 2005-02-28 2006-08-31 Ktb Tumorforschungsgesellschaft Mbh Proteinbindende Camptothecin-Peptid-Derivate und diese enthaltende Arzneimittel
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
JP2006316040A (ja) * 2005-05-13 2006-11-24 Genentech Inc Herceptin(登録商標)補助療法
PT2032606E (pt) 2006-05-30 2014-02-05 Genentech Inc Anticorpos e imunoconjugados e respetivas utilizações
CN101490087B (zh) 2006-05-30 2013-11-06 健泰科生物技术公司 抗体和免疫偶联物及其用途
NZ588884A (en) 2008-04-30 2013-05-31 Immunogen Inc Cross-linkers and their uses
US8541178B2 (en) 2008-05-13 2013-09-24 Genentech, Inc. Analysis of antibody drug conjugates by bead-based affinity capture and mass spectrometry
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
PL3912643T3 (pl) 2009-02-13 2023-01-23 Immunomedics Inc. Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo
EP2456464A4 (en) 2009-07-22 2013-02-20 Enzon Pharmaceuticals Inc METHOD FOR THE TREATMENT OF HER2-POSITIVE CANCER WITH HER2 RECEPTOR ANTAGONISTS IN COMBINATION WITH MULTICARM POLYMER CONJUGATES FROM 7-ETHYL-10-HYDROXYCAMPTOTHECIN
CA2775350A1 (en) 2009-09-24 2011-03-31 Seattle Genetics, Inc. Dr5 ligand drug conjugates
IN2012DN03354A (enExample) 2009-12-02 2015-10-23 Immunomedics Inc
US8609095B2 (en) * 2010-03-04 2013-12-17 Symphogen A/S Anti-HER2 antibodies and compositions
ES2661228T3 (es) 2010-05-13 2018-03-28 Indiana University Research And Technology Corporation Péptidos de la superfamilia de glucagón que muestran actividad de receptor nuclear de hormona
CA2927832C (en) 2010-05-18 2021-03-23 Cerulean Pharma Inc. Cyclodextrin-containing polymer-therapeutic agent conjugates and their use
SG186451A1 (en) 2010-07-12 2013-01-30 Covx Technologies Ireland Ltd Multifunctional antibody conjugates
EP2640727B1 (en) 2010-11-17 2015-05-13 Genentech, Inc. Alaninyl maytansinol antibody conjugates
MX2014007121A (es) 2011-12-14 2014-09-04 Seattle Genetics Inc Nuevos conjugados de principio activo-ligante (adc) y su uso.
US20130280282A1 (en) 2012-04-24 2013-10-24 Daiichi Sankyo Co., Ltd. Dr5 ligand drug conjugates
MX2014015205A (es) 2012-06-14 2015-08-14 Ambrx Inc Anticuerpos anti-psma conjugados a polipeptidos de ligando de receptor nuclear.
US10195288B2 (en) 2012-10-11 2019-02-05 Daiichi Sankyo Company, Limited Antibody-drug conjugate
EP2910573B1 (en) 2012-10-19 2020-02-19 Daiichi Sankyo Company, Limited Antibody-drug conjugate produced by binding through linker having hydrophilic structure
EP2927227A4 (en) 2013-01-03 2015-12-30 Celltrion Inc ANTIBODY CONCENTRATOR REMEDY CONJUGATE, METHOD OF MANUFACTURING THEREOF, AND ANTIBODY TOGETHER THEREWITH
SG11201603960XA (en) 2014-01-31 2016-07-28 Daiichi Sankyo Co Ltd Anti-her2 antibody-drug conjugate

Similar Documents

Publication Publication Date Title
JP7608164B2 (ja) 抗体-薬物コンジュゲートとparp阻害剤の組み合わせ
JP2024075668A (ja) 抗体-薬物コンジュゲートとチューブリン阻害剤の組み合わせ
JP2021059564A (ja) 癌治療のための併用療法
IL312038A (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
JP2020525542A5 (enExample)
TWI868465B (zh) 抗her2抗體-藥物結合物之用途
JP2023525120A5 (enExample)
JP2021501776A5 (enExample)
AU2019278628B2 (en) Treatment of HER2-mutated cancer by administering anti-HER2 antibody-drug conjugate
JP2021515017A5 (enExample)
JP2012522512A5 (enExample)
RU2007101378A (ru) Терапия злокачественной опухоли, резистентной к препаратам на основе платины
JP6425653B2 (ja) 抗腫瘍剤及び抗腫瘍効果増強剤
JP2022519273A5 (enExample)
JP2019524713A5 (enExample)
JP2023510349A5 (enExample)
JP7449583B2 (ja) 標的特異的複合体及びその用途
JP2021511372A5 (enExample)
JP2026504636A5 (enExample)
JP2024542095A5 (enExample)
JP2025517908A5 (enExample)
JP2024536383A5 (enExample)
JP2025513620A (ja) 抗体-薬物コンジュゲートとezh1阻害剤および/またはezh2阻害剤との組合せ
JPWO2022019259A5 (enExample)
JP2024502465A5 (enExample)